title: Use of ampicillin-sulbactam for treatment of experimental meningitis caused by a beta-lactamase-producing strain of Escherichia coli K-1.
abstract: We evaluated the pharmacokinetics and therapeutic efficacy of ampicillin combined with sulbactam in a rabbit model of meningitis due to a beta-lactamase-producing strain of Escherichia coli K-1. Ceftriaxone was used as a comparison drug. The MIC and MBC were 32 and greater than 64 micrograms/ml (ampicillin), greater than 256 and greater than 256 micrograms/ml (sulbactam), 2.0 and 4.0 micrograms/ml (ampicillin-sulbactam [2:1 ratio, ampicillin concentration]) and 0.125 and 0.25 micrograms/ml (ceftriaxone). All antibiotics were given by intravenous bolus injection in a number of dosing regimens. Ampicillin and sulbactam achieved high concentrations in cerebrospinal fluid (CSF) with higher dose regimens, but only moderate bactericidal activity compared with that of ceftriaxone was obtained. CSF bacterial titers were reduced by 0.6 +/- 0.3 log10 CFU/ml/h with the highest ampicillin-sulbactam dose used (500 and 500 mg/kg of body weight, two doses). This was similar to the bactericidal activity achieved by low-dose ceftriaxone (10 mg/kg), while a higher ceftriaxone dose (100 mg/kg) produced a significant increase in bactericidal activity (1.1 +/- 0.4 log10 CFU/ml/h). It appears that ampicillin-sulbactam, despite favorable CSF pharmacokinetics in animals with meningitis, may be of limited value in the treatment of difficult-to-treat beta-lactamase-producing bacteria, against which the combination shows only moderate in vitro activity.
authors.affiliation: Medical Service, San Francisco General Hospital, California.
authors.forename: L
authors.initials: L
authors.lastname: Guerra-Romero
authors.forename: S L
authors.initials: SL
authors.lastname: Kennedy
authors.forename: M A
authors.initials: MA
authors.lastname: Fournier
authors.forename: J H
authors.initials: JH
authors.lastname: Tureen
authors.forename: M G
authors.initials: MG
authors.lastname: Täuber
mesh_terms: D000667:Ampicillin / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D002443:Ceftriaxone / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics / Q000627:therapeutic use; D004927:Escherichia coli Infections / Q000188:drug therapy* / Q000382:microbiology; D007275:Injections, Intravenous; D016920:Meningitis, Bacterial / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D008826:Microbial Sensitivity Tests; D011817:Rabbits; D013407:Sulbactam / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001618:beta-Lactamases / Q000096:biosynthesis*
chemical_list: C035444:sultamicillin; D002443:Ceftriaxone; D000667:Ampicillin; D001618:beta-Lactamases; D013407:Sulbactam